Pennsylvania State Court Jury Awards $500,000 In Risperdal Gynecomastia Trial

(December 14, 2015, 10:14 AM EST) -- PHILADELPHIA — After a three-week hiatus for the production of newly discovered defense data about the safety of Risperdal and three more days of testimony, a Pennsylvania state court jury on Dec. 11 found that Janssen Pharmaceuticals Inc. and parent company Johnson & Johnson failed to warn a physician about the risk of gynecomastia to a 12-year-old boy and awarded the plaintiff compensatory damages of $500,000, plaintiff attorney Tom Kline of Kline & Specter in Philadelphia told Mealey Publications (Timothy Stange v. Janssen Pharmaceuticals, Inc., et...
To view the full article, register now.